NEW YORK, July 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).
Executive Summary•The market for psoriatic arthritis (PsA) pharmacotherapeutics is currently comprised of a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for anti-TNF refractory patients represents a significant unmet need.•Revenue generated from sales of TNF inhibitors for PsA in the United States was approximately $xxx.x million in 2011 and dominated by Amgen. Revenue for the PsA therapeutic area is expected to increase to approximately $x,xxx.x million in 2017, aided by the addition of several new therapies to the market.•Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.•Development of therapies for this complex disease and market penetration is hindered by several factors including a perception of PsA as a milder disease compared to rheumatoid arthritis (RA), and incompletely understood pathogenesis.•Although some therapies such as TNF inhibitors that are effective for the treatment of RA are also effective for PsA, this is not always the case due to differences between the two diseases.•Accumulating evidence supporting the importance of prompt initiation of effective disease modifying therapy for better long-term outcomes for patients with PsA is driving development of novel therapies aimed at improving symptoms and slowing disease progression.•Estimates of the prevalence of PsA vary widely, but it is generally considered to occur in approximately xx to xx percent of psoriasis sufferers, or approximately xxx,xxx to x.x million men and women in the United States.•Diagnostic difficulties are thought to result in unawareness of the condition by many patients and significant under-treatment.
TABLE OF CONTENTS
Executive Summary 4
Market Overview 10
Psoriatic Arthritis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 20
Forecast and Trends 30
Demand Analysis 41
Market Share and Competitive Analysis 44
TNF Inhibitor Segment Breakdown 54
Non-TNF Biologics Segment Breakdown 65
Novel Oral DMARDs Segment Breakdown 73
The Last Word 81
To order this report: Pathology Industry: United States Market for Psoriatic Arthritis Pharmacotherapy
Nicolas Bombourg Reportlinker Email: firstname.lastname@example.org US: (805)652-2626 Intl: +1 805-652-2626
Copyright©2012 PR Newswire.
All rights reserved